Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
Loading...
Date
Authors
Richardson, Simone I.
Kgagudi, Prudence
Manamela, Nelia P.
Kaldine, Haajira
Venter, Elizabeth M.
Pillay, Thanusha
Lambson, Bronwen E.
Van der Mescht, Mieke Adri
Hermanus, Tandile
Balla, Sashkia R.
Journal Title
Journal ISSN
Volume Title
Publisher
Cell Press
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody dependent cellular cytotoxicity (ADCC) potential, measured by FcgRIIIa signaling, in convalescent donors infected with four previous variants of SARS-CoV-2, as well as in post-vaccination breakthrough infections (BTIs) caused by Delta or BA.1. We confirm that BA.4 shows high-level neutralization resistance regardless
of the infecting variant. However, BTIs retain activity against BA.4, albeit at reduced titers. BA.4 sensitivity to ADCC is reduced compared with other variants but with smaller fold losses compared with neutralization and
similar patterns of cross-reactivity. Overall, the high neutralization resistance of BA.4, even to antibodies from BA.1 infection, provides an immunological mechanism for the rapid spread of BA.4 immediately after a BA.1-dominated wave. Furthermore, although ADCC potential against BA.4 is reduced, residual activity may contribute to observed protection from severe disease.
Description
Keywords
Breakthrough infections, Protection, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Omicron BA.4, Omicron BA.5, Antibodydependent cellular cytotoxicity (ADCC), Binding, Neutralization, SDG-03: Good health and well-being
Sustainable Development Goals
SDG-03:Good heatlh and well-being
Citation
Richardson, S.I., Kgagudi, P., Manamela, N.P. et al. 2023, 'Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant', Cell Reports Medicine, vol. 4, art. 100910, pp. 1-10. https://DOI.org/10.1016/j.xcrm.2022.100910